Antimicrobial Resistance Investment Map and Funding

Overview

• The Antimicrobial Resistance (AR) Investment Map showcases CDC activities to combat antimicrobial resistance. The map currently shows fiscal year 2025 extramural funds that support CDC's antimicrobial resistance activities.
• CDC supports health departments and public health laboratories to detect and respond to drug-resistant threats.
• CDC invests in innovative research projects to identify and implement new ways to comprehensively respond to antimicrobial resistance.

Through these investments, CDC is transforming how the nation and world combat antimicrobial resistance. For example, CDC is:

• Equipping all states and several territories and large cities with lab expertise through CDC's Antimicrobial Resistance Laboratory Network (AR Lab Network) and on-the-ground experts to contain outbreaks of resistant germs.
• Improving antibiotic and antifungal use across healthcare and veterinary settings.
• Enhancing detection and tracking of antimicrobial-resistant pathogens for local prevention of healthcare-associated, foodborne, and community threats such as drug-resistant tuberculosis, carbapenem-resistant Enterobacterales, Candida auris, and gonorrhea.
• Spurring innovation through research investments using a One Health approach to identify and implement new ways to combat antimicrobial resistance.
• Informing the development of new drugs and diagnostics by sharing isolates (pure samples of a germ) and CDC sequencing data.
• Supporting partners through the Global Antimicrobial Resistance Laboratory and Response Network (Global AR Lab & Response Network) to detect and respond to AR threats across One Health.

AR Investment Map

View Larger

Visit the AR Investment Map

The map currently shows fiscal year 2025 extramural funds that support CDC's antimicrobial resistance activities. CDC distributed the largest extramural portion of funding to support all 50 state health departments, as well as health departments in several U.S. territories and large cities. The map also includes fact sheets highlighting CDC's innovation work with partners to combat antimicrobial resistance. The information is updated yearly.

Investment successes

CDC's investments in innovation to combat AR since 2016 include:

• Funding more than 900 innovation projects.
• Collaborating with more than 200 public and private institutions.
• Investing more than $680 million to address knowledge gaps with scalable solutions.
• Awarding more than $57 million through the Broad Agency Announcement (a specific funding mechanism).
• Filling more than 13,500 isolate panel orders through the Antimicrobial Resistance Isolate Bank, totaling more than 500,00 isolates shipped.

Funding recipients

CDC supports innovations and collaborations with investigators to identify and implement new ways to prevent antimicrobial-resistant infections and their spread. CDC supports innovative research to slow antimicrobial resistance through various funding mechanisms.

The projects complement additional CDC antimicrobial resistance investments, collectively known as CDC's AR Solutions Initiative. Through these investments, CDC is transforming how the nation combats antimicrobial resistance at all levels.

Funding opportunities

CDC supports activities carried out by state and local health departments, partners, and investigators to combat antimicrobial resistance. CDC supports most of these activities through the Antimicrobial Resistance (AR) Solutions Initiative, and leverages investments from successful programs across the agency for maximum efficiency. These activities are funded through different mechanisms, some of which are listed below.

CDC funding solicitation and award announcements change from year to year. Visit FedBizOpps to find current opportunities and exact deadlines throughout the Federal Government. Find the latest CDC antimicrobial resistance activities by state on the AR Investment Map.